Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| FEDERAL MOGU | FDML | 6.78% |
| SUMMER INFAN | SUMR | 6.63% |
| NEW ORIENTAL | EDU | 6.53% |
| NATUS MEDICA | BABY | 5.90% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Electronic Manufacturing Services provider Plexus Corp ( PLXS - Analyst Report ) is scheduled to announce its fiscal third quarter 2012 results after the closing bell on July 18, 2012. In the run up to the earnings release, we have noticed some analysts revising their estimates downward.
However, we note that Plexus has outperformed the Zacks Consensus Estimate in the preceding four quarters by a positive 5.34%. We expect this trend to continue in the current quarter.
Previous Quarter Highlights
Plexus’s top line inched down 1% in the second quarter on a year-over-year basis. Weaker-than-expected sales from its Networking/Communications segment and Medical segment, which more than offset the robust performances from its Industrial/Commercial and Defense/ Security/Aerospace segments, were responsible for the year-on-year decline.
However, Plexus’s revenue of $573.5 million was within management’s guided range of $550.0 million to $580.0 million, and also surpassed the Zacks Consensus Estimate of $566.0 million.
The company’s bottom line shrunk 5.0% on a year-over-year basis to 56 cents, primarily due to higher interest expense and tax rate in the quarter. However, the reported earnings surpassed the Zacks Consensus Estimate by a couple of cents and were within management’s guided range of 51 cents to 58 cents per share.
For further details please read: Plexus Tops Estimates in 2Q
Estimate Revision Trend
In the last 30 days, two out of the eight analysts covering the stock revised their estimates downward, with no upward revisions. However, the Zacks Consensus Estimate for the third quarter of 2012 stayed at 63 cents, which is at the mid-point of management’s guided range of 60 cents and 66 cents per share.
For the third quarter, the Zacks Consensus revenue estimate is $607.0 million, which is also within management’s guidance range of $590.0 million to $620.0 million.
Concerns in the network and communications segment of the company, which is likely to be affected by Juniper Networks Inc.’s ( JNPR - Analyst Report ) dismal performance, keep the analysts cautious. Approximately 40% of Plexus’ communications revenue comes from Juniper. However, analysts expect other segments like the Industrial, Medical, and Aerospace to positively impact the top line on the back of new program wins.
The company’s expansionary initiatives across Romania, Scotland, Mexico, Malaysia and China are expected to affect the operating cash flow in the short run. However, expanding into the above-mentioned low-cost regions would be a positive for the company in the longer run.
Recommendation
We believe that stabilizing end markets, new business opportunities, particularly in the industrial/commercial and medical sector and global expansion will drive growth over the long term. We also believe that the gradual improvement in the U.S. market will boost Plexus’ top line going forward. However, intense competition, continued component challenges and supply chain constraints remain major concerns for Plexus over the long term.
Thus, we have Neutral recommendation on Plexus over the long term (6-12 months). Currently, Plexus has a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Analyst Report on PLXS
Read the full Analyst Report on JNPR